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ABSTRACT
Infection by Pseudomonas aeruginosa has spread worldwide, with limited options for treatment. The 
purpose of this study was to investigate metallo-β-lactamase-producing P. aeruginosa strains and 
compare their genetic profile using samples collected from patients in intensive care units. Forty 
P. aeruginosa strains were isolated from two public hospitals in Campo Grande, Mato Grosso do Sul 
State, from January 1st, 2007 to June 31st, 2008. Profiles of antimicrobial susceptibility were deter-
mined using the agar diffusion method. Metallo-β-lactamase was investigated using the double-disk 
diffusion test and PCR. Molecular typing was performed by pulsed-field gel electrophoresis (PFGE). 
Respiratory and urinary tracts were the most common isolation sites. Of the 40 samples tested, 72.5% 
(29/40) were resistant to ceftazidime and 92.5% (37/40) to imipenem, whereas 65% (26/40) were re-
sistant to both antimicrobials. Fifteen pan-resistant samples were found. Five percent (2/40) of sam-
ples were positive for metallo-β-lactamase on the phenotype test. No metallo-β-lactamase subtype 
was detected by PCR. Macrorestriction analysis revealed 14 distinct genetic patterns. Based on the 
superior accuracy of PCR, it can be inferred that P. aeruginosa isolates from the investigated hospi-
tals have alternative mechanisms of carbapenem resistance. The results also suggest clonal spread of 
P. aeruginosa between the studied hospitals. 
Keywords: Pseudomonas aeruginosa; drug resistance, multiple; beta-lactamases; electrophoresis; gel; 
pulsed-field.
[Braz J Infect Dis 2011;15(3):195-199]©Elsevier Editora Ltda.
INTRODUCTION
Pseudomonas aeruginosa, a non-fermenting 
Gram-negative rod of great clinical and epide-
miological relevance in hospital-acquired infec-
tions, is more frequently found in intensive care 
units (ICUs)1 and is associated with high mor-
bimortality.2 
The selective pressure exerted by the indis-
criminate use of antimicrobial agents in the last 
decades might have contributed to the emer-
gence of microorganisms that are resistant to 
different classes of antibiotics and is currently a 
matter of worldwide concern.3 Several mecha-
nisms are involved in P. aeruginosa resistance to 
antimicrobial agents, such as chromosomal ex-
pression, β-lactamase production, efflux pumps 
and decrease in membrane permeability.4 
The currently observed increased resistance 
to carbapenem has stimulated studies aiming at 
a better understanding of the resistance mecha-
nisms of P. aeruginosa.3,5,6 The emergence and 
dissemination of metallo-β-lactamases (MBL) 
have contributed to the high rate of resistance 
among the P. aeruginosa strains isolated in the 
last decades. The MBL production knowledge is 
crucial to implement preventive measures that 
can curb the expansion of bacteria presenting 
this potent resistance gene.3 
The objective of the present study was to 
investigate metallo-β-lactamase and genetic 
similarity among P. aeruginosa strains isolated 
in ICUs of two hospitals in the city of Campo 
Grande, state of Mato Grosso do Sul, Brazil. 
MATERIALS AND METHODS 
Research site and period
The study was carried out with P. aeruginosa 
strains from patients admitted at adult ICUs, 
coronary care units (CCUs) and pediatric 
ICUs (PICUs) of two public hospitals in the state 
of Mato Grosso do Sul, Brazil, from 01/01/2007 to 
06/31/08. Hospital A is a 250-bed university hos-
pital and hospital B is a 360-bed tertiary hospital.
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Inclusion criteria
P. aeruginosa strains resistant to ceftazidime and/or imipenem, 
isolated from several types of biological material were included 
in the study. One sample was obtained from each patient and 
stored in a strain bank at the hospitals. These strains were ran-
domly selected without distinction regarding infection or colo-
nization and were not obtained from surveillance cultures. 
Bacterial identification and susceptibility to antibiotic 
agents 
P. aeruginosa isolates were identified using conventional meth-
odology.7 The antimicrobial susceptibility was determined 
by the agar diffusion method, according to the Clinical Labora-
tory Standard Institute (CLSI) recommendations.8 The tested 
antibiotics were polymyxin – POL (10 µg), tazobactam + piper-
acillin – TZP (100/10 µg), imipenem – IPM (10 µg), meropen-
em – MER (10 µg), amikacin – AMI (30 µg), gentamicin – GEN 
(10 µg), aztreonam – ATM (30 µg), cefepime – CPM (30 µg), 
ceftazidime – CAZ (30 µg) and ciprofloxacin – CIP (5 µg). 
P. aeruginosa strains sensitive to polymyxin B only were consid-
ered pan-resistant. 
MBL detection 
MBL was detected using a phenotypic disc method as described 
by Arakawa et al.,9 with the modifications suggested by Picão et 
al.10 The samples were suspended in saline solution (0.5 in the 
McFarland turbidity scale) and seeded with a sterile swab on an 
Oxoid Mueller-Hinton Agar dish. The ceftazidime (30 µg) and 
imipenem (10 µg) discs were placed at a 2-cm distance from a 
disc without antibiotic agent, which received 5 µL of 2-mercap-
topropionic acid solution diluted 1:8. After incubation at 37ºC 
for 16 to 18 hours, samples that presented an increase in halo 
size around the ceftazidime or imipenem discs were considered 
positive. A standard strain of P. aeruginosa (SPM-1, P1088) was 
used as positive control, which was kindly provided by ALER-
TA Laboratory - UNIFESP.
P. aeruginosa strains positive for MBL production at the 
phenotypic test were submitted to conventional PCR.11 The 
starter oligonucleotides used were: blaSPM-1 F (5´CCT ACA 
ATC TAA CGG CGA CC3´) and R (5´TCG CCG TGT CCA 
GGT ATA AC3´), blaIMP-1 F (5´CTA CCG CAG CAG AGT 
CTT TTG3´) and R (5´AAC CAG TTT TGC CTT ACC 
AT3´) blaIMP-2 F (5’GTT TTA TGT GTA TGC TTC CTT 
TGT AGC3’) and R (5’CAG CCT GTT CCC ATG TAC G3’), 
blaVIM-1 F (5’GTT TGG TCG CAT ATC GCA AC3’) e R 
(5’AGA CCG CCC GGT AGA CC3’), blaVIM-2 F (5´ATG 
AAA GTG CGT GGA GAC3´) and R (5’CTA CTC AAC GAC 
TGA GCG ATT TGT3’).12,13
Pulsed field gel electrophoresis
Genotype determination was carried out by pulsed field gel 
electrophoresis (PFGE), according to Romao et al.14 Chromo-
somal DNA was prepared using the in situ technique in agarose 
blocks. A bacterial suspension at the exponential growth phase 
was added to a 400 µL of BSC solution (Tris 1 M, pH 8.0, EDTA 
0.5 M). After that, 5 µL of proteinase K (Sigma) and 200 µL of 
1% agarose (low melting) were added to the cell suspension. The 
mixture was distributed in molds. The blocks were transferred 
to a lyse solution (TRIS 1 M, pH 8.0; EDTA 0.5 M, pH 8.0 and 
10% N-lauryl sarcosine + 5 µL of proteinase K) and incubated 
at 50ºC for 24 hours. Subsequently, the molds were washed six 
times with TE buffer at 37ºC and incubated with enzyme buffer 
for one hour at 5ºC. After buffer removal, the molds were in-
cubated with restriction enzyme SpeI (Invitrogen) at 37ºC for 
2 hours. The electrophoresis procedure was carried out by 
PFGE in 1% agarose gel and run with a buffer containing 0.4X 
Tris Borato EDTA in the CHEF DR II system (BioRad, Cali-
fornia). The gel run consisted in a crescent pulse time of 5 to 
25s, for 18 hours at 6 V/cm at a temperature of 14ºC, with an 
angle of 120º. The fragments were stained with ethidium bro-
mide and photographed. The band profile was analyzed using 
the Gel Compar III system (Applied Maths, Belgium). The den-
drogram was generated using the UPGMA algorithm.
RESULTS
A total of 40 strains of P. aeruginosa were analyzed, of which 
12 were isolated from hospital A and 28 from hospital B. Of 
the total number of samples, 36 came from the adult inten-
sive care unit (ICU), 3 from the coronary care unit (CCU) 
and 1 from the pediatric ICU. The samples were isolated from 
several sites: tracheal aspirate (17; 42.5%), urine (13; 32.5%), 
catheter tip (4; 10%), blood (2; 5%) and others (4; 10%), such 
as pressure ulcer secretion, sacral ulcer and trochanteric ulcer.
Table 1 shows the percentage of resistance in the pres-
ence of the tested antimicrobial agents. Of the total strains, 
72.5% (29/40) were resistant to ceftazidime, 92.5% (37/40) to 
imipenem and 65% (26/40) had simultaneous resistance 
to both antimicrobials. Approximately 37.5% of the strains 
were considered pan-resistant. All samples were sensitive in 
vitro to polymyxin B.
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Table 1. Antimicrobial resistance of P. aeruginosa in 
ICUs, Campo Grande/MS
Antimicrobial agents Resistance % (n = 40)
Cefepime 95
Imipenem 92.5
Ciprofloxacin 90
Gentamicin 85
Aztreonam 85
Amikacin 72.5
Ceftazidime 72.5
Meropenem 70
Tazobactam + piperacillin  70
Polymyxin 00
ICUs, intensive care units.
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Table 2. Phenotypic and molecular profile of P. aeruginosa, Campo Grande/MS
Profile Patterns of resistance  Hosp PFGE Number of samples
01 PPT/AMI/ATM/CPM/CAZ/CIP/GEN/IPM/MER
 HB A/B/D/E 07/1/1/1
  HA A/B/J 1/2/1
02 PPT/AMI/ATM/CAZ/CIP/GEN/IPM/MER HB G 1
03 PPT/CPM/ATM/CAZ/CIP/GEN/IPM HB A 1
04 CIP/GEN/IPM HB C 1
05 AMI/CPM/CIP/GEN/IPM HB C/E 1/1
06 CPM/GEN/CIP/IPM HB C 1
07 PPT/AMI/ATM/CPM/CAZ/CIP/GEN HB C 1
08 AMI/ CPM/ ATM/ CIP/ GEN/ IPM/ MER
 HB B/C/K 1/1/1
  HA B 2
09 PPT/ ATM/CPM/CAZ/IPM HB I 1
10 PPT/ ATM/CPM/CAZ/GEN/IPM HB D 3
11 PPT/ ATM/CPM/CAZ/GEN HB M 1
12 PPT/AMI/CPM/CAZ/CIP/GEN/IPM HB J 1
13 ATM/CPM/CAZ/CIP/IPM/MER HA N 1
14 PPT/ATM/CPM/CAZ/IPM/MER HB C 1
15 PPT/AMI/ATM/CPM/CIP/GEN/IPM/MER
 HB F/H 1/1
  HA F 1
16 AMI/CPM/CAZ/CIP/GEN/IPM/MER HA  L 1
17 AMI/ATM/CPM/CAZ/CIP/GEN/IPM/MER HA E/K 1/1
PFGE, pulsed field gel electrophoresis; AMI, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin;  
CPM, cefepime; GEN, gentamicin; IPM, imipenem; MER, meropenem; PPT, piperacillin + tazobactam; POL, polymyxin;  
Hosp, hospital; HA, hospital A; HB, hospital B.
Table 3. Period and hospital where P. aeruginosa was isolated with PFGE profile A
Register  Hospital Date  Clinic Underlying disease Material
1777 HB 09/01/06 Adult ICU Kidney disease U
1694 HB 21/02/06 Adult ICU Neurological disease  TA
1695 HB 07/03/06 Adult ICU Neurological disease TA
1696 HB 17/04/06 Adult ICU Diabetes mellitus U
1770 HA 26/6/06 Adult ICU Heart disease U
1701 HB 11/07/06 CCU Respiratory disease  TA
1712 HB 27/11/06 Adult ICU Liver disease BL
1718 HB 23/03/07 Adult ICU AIDS CT
1726 HB 08/11/07 Adult ICU Respiratory disease  TA
PFGE, pulsed field gel electrophoresis; ICU, intensive care unit; CCU, coronary care unit; AIDS, acquired immune  
deficiency syndrome; U, urine; TA, tracheal aspirate; BL, blood ; CT, catheter tip; HA, hospital A; HB, hospital B.
Table 2 shows 17 different bacterial resistance patterns: 
six were found in hospital A and 14 in hospital B. Three re-
sistance patterns (numbers 1, 8 and 15) were found in both 
hospitals studied.
The phenotypic test to detect MBL was positive in 5% 
(2/40) of P. aeruginosa isolates; however, none of the genes in-
vestigated (bla-IMP, bla-VIM and bla-SPM) was identified by 
PCR. The molecular analysis generated by the PFGE disclosed 
14 distinct genetic patterns (A to N). Table 2 shows some 
common profiles (A, B, E, F, J, K) at the two hospital institu-
tions. Profile A was the most frequent (n = 9), of which one 
strain was from hospital A and eight from hospital B (Table 3). 
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DISCUSSION
Patients with preexisting comorbidities, long hospital 
stay and those submitted to invasive procedures such as 
catheters and mechanical ventilation make the ICUs propi-
tious places for P. aeruginosa dissemination,15,16 very often 
associated with high levels of morbimortality.17
P. aeruginosa was isolated mainly from materials such 
as tracheal aspirate and urine, corroborating the literature 
data reporting that this agent is more often isolated from the 
lower respiratory and urinary tracts.18-20
Resistance to different classes of antibiotics has been 
attributed to the combination of multiple mechanisms,4 
which might explain the diversity of resistance patterns 
shown in Table 2.
The use of the lipopeptide class, such as polymyxin B and 
colistin, was abandoned for a while due to the high toxicity, 
but recently, it has once again become an important thera-
peutic option for multiresistant microorganism infections.21 
Supporting this concept at the present investigation, all 
P. aeruginosa strains were sensitive to this drug.
The analysis of the susceptibility profile in vitro dem-
onstrated higher levels of resistance in the presence of 
cefepime, imipenem and ciprofloxacin, drugs used in the 
treatment of severe Pseudomonas infections. On the other 
hand, as shown in Table 1, tazobactam in combination with 
piperacillin, meropenem and ceftazidime were the drugs 
that demonstrated the lowest resistance, suggesting that 
these drugs, as well as polymyxin, can be used as therapeutic 
option for P. aeruginosa infection in both institutions. The 
higher resistance of cefepime when compared to ceftazidime 
might indicate the presence of OXA-31, an oxacillinase that 
has cefepime as its preferential substrate.22 
The dissemination capacity of MBL that hydrolyses 
expanded-spectrum β-lactams, including cephalosporins 
and carbapenems, has been a matter of great concern in the 
world. Studies in several parts of the world have demonstrat-
ed varied rates of MBL production by P .aeruginosa, such 
as 6.2% in Korea,6 35% in Canada,5 and 62% in Greece.23 
In Brazil, the SPM subtype has been described as the most 
prevalent in several regions of the country. National data 
have reported different rates of MBL production, which vary 
according to the institution and the studied region. As an 
example, one could cite rates of 10.9% in hospitals in Rio 
Grande do Sul,24 20% in Rio de Janeiro – RJ,25 and 41.9% 
in the state of Goiás.26 Figueiredo-Mendes et al.27 described 
higher rates of this enzyme production (77.8%) among 
P. aeruginosa strains previously resistant to carbapenems in 
hospitals in São Paulo and Brasília. 
Different from what is observed in other Brazilian re-
gions, our series did not show the presence of MBL-produc-
ing P. aeruginosa. Further studies with larger sample sizes 
are necessary to detect the emergence of this important re-
sistance gene in hospitals in the state of Mato Grosso do Sul. 
The fact that the genes bla-SPM, bla-IMP and bla-VIM were 
not detected even in samples with a positive phenotypic test 
for MBL suggests the unreliability of the phenotypic test that 
was applied. 
The finding of identical genetic profiles generated by 
PFGE in the two hospitals suggests an inter-hospital dis-
semination of P. aeruginosa. The high rate of healthcare 
professional and patient turnover between the hospitals and 
hospital wards might have contributed to these results. 
The distribution of P. aeruginosa with A profile (Table 3) 
suggests inter-hospital transmission, as it was initially found 
in the adult ICU and it was subsequently found at the CCU 
of hospital B. This clone (A profile) was also isolated at dif-
ferent periods, which might indicate that it is endemic 
in this hospital. It is noteworthy the fact that many strains 
with this profile were sensitive only to polymyxin B, which 
shows high resistance of strains with this genetic pattern. 
CONCLUSION
The results suggest that the resistance of P. aeruginosa to 
carbapenem agents in the present study is due to resistance 
mechanisms other than MBL production. The inter-hos-
pital and intra-hospital clonal dissemination is a matter of 
concern and must be contained through preventive hospi-
tal infection control measures. Considering the emergent 
characteristic of MBL, its surveillance becomes important to 
control the transmission of this resistance mechanism. 
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